Oral Immunization with <i>Helicobacter pylori</i>‐Loaded Poly(					<scp>d</scp>,					<scp>l</scp>‐Lactide‐Co‐Glycolide) Nanoparticles

Kim, Seong-Youl; Doh, H.J; Jang, Myoung Ho; Ha, Y.J; Chung, Soo‐Il; Park, Hae‐Joon

doi:10.1046/j.1523-5378.1999.09046.x

Cited by 58 publications

(18 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…131 However, antibody titers of groups immunized with H. pylori -loaded PLGA nanoparticles were lower than particles immunized containing free H. pylori protein associated with the CTB. Fattal et al 135 showed protection of mice against following oral administration of Salmonella typhimurium antigen-encapsulated PLGA particles.…”

Section: Macro- and Nano-particle Inducers Of Immunity And Tolerancementioning

confidence: 97%

Past, Present, and Future Technologies for Oral Delivery of Therapeutic Proteins

Singh

Lillard

2008

Journal of Pharmaceutical Sciences

163

View full text Add to dashboard Cite

Biological drugs are usually complex proteins and cannot be orally delivered due to problems related to degradation in the acidic and protease-rich environment of the gastrointestinal (GI) tract. The high molecular weight of these drugs often results in poor absorption into the periphery when administered orally. The most common route of administration for these therapeutic proteins is injection. Most of these proteins have short serum half-lives and need to be administered frequently or in high doses to be effective. So, difficulties in the administration of protein-based drugs provides the motivation for developing drug delivery systems (DDSs) capable of maintaining therapeutic drug levels without side effects as well as traversing the deleterious mucosal environment. Employing a polymer as an entrapment matrix is a common feature among the different types of systems currently being pursued for protein delivery. Protein release from these matrices can occur through various mechanisms, such as diffusion through or erosion of the polymer matrix, and sometimes a combination of both. Encapsulation of proteins in liposomes has also been a widely investigated technology for protein delivery. All of these systems have merit and our worthy of pursuit.

show abstract

Section: Macro- and Nano-particle Inducers Of Immunity And Tolerancementioning

confidence: 97%

Past, Present, and Future Technologies for Oral Delivery of Therapeutic Proteins

Singh

Lillard

2008

Journal of Pharmaceutical Sciences

163

View full text Add to dashboard Cite

show abstract

“…Different lectins, bacterial adhesins, and RGD analogs have been used to target M cells and the oral epithelial cells [55]. Nanoparticles based on polylactic acid (PLA) or poly(lactic-co-glycolic acid) (PLGA) polymers have been extensively explored for oral vaccination with a variety of antigens like bovine serum albumin [94], inactivated bacteria [95], their toxoids [96], and DNA [97]. PLGA and PLA are known to be biocompatible and biodegradable.…”

Section: Mucosal Vaccine Delivery Systemsmentioning

confidence: 99%

Mucosal vaccine delivery: Current state and a pediatric perspective

Shakya

Chowdhury

Tao

et al. 2016

Journal of Controlled Release

121

115

View full text Add to dashboard Cite

Most childhood infections occur via the mucosal surfaces, however, parenterally delivered vaccines are unable to induce protective immunity at these surfaces. In contrast, delivery of vaccines via the mucosal routes can allow antigens to interact with the mucosa-associated lymphoid tissue (MALT) to induce both mucosal and systemic immunity. The induced mucosal immunity can neutralize the pathogen on the mucosal surface before it can cause infection. In addition to reinforcing the defense at mucosal surfaces, mucosal vaccination is also expected to be needle-free, which can eliminate pain and the fear of vaccination. Thus, mucosal vaccination is highly appealing, especially for the pediatric population. However, vaccine delivery across mucosal surfaces is challenging because of the different barriers that naturally exist at the various mucosal surfaces to keep the pathogens out. There have been significant developments in delivery systems for mucosal vaccination. In this review we provide an introduction to the MALT, highlight barriers to vaccine delivery at different mucosal surfaces, discuss different approaches that have been investigated for vaccine delivery across mucosal surfaces, and concludes with an assessment of perspectives for mucosal vaccination in the context of the pediatric population.

show abstract

“…The benefits of PLGA nanoparticles for any biomedical applications is they slowly degrade when exposed to water, meaning they can protect hydrophobic, hydrophilic, small molecule, or biological macromolecule cargo and release it over an extended period of time [117]. In preclinical studies this has been demonstrated to be an effective carrier in mouse models for vaccines composed of HBsAg, tetanus toxoid, Helicobacter pylori lysate, Listeria monocytogenes antigens, malaria antigens, and B. anthracis spores [116,[118][119][120][121][122][123][124][125]. These vaccines are able to generate long lasting humoral and cellular immune response.…”

Section: Nanotechnology and Nanovaccinesmentioning

confidence: 99%

Vaccine technologies: From whole organisms to rationally designed protein assemblies

Karch¹,

Burkhard²

2016

Biochemical Pharmacology

215

185

View full text Add to dashboard Cite

Vaccines have been the single most significant advancement in public health, preventing morbidity and mortality in millions of people annually. Vaccine development has traditionally focused on whole organism vaccines, either live attenuated or inactivated vaccines. While successful for many different infectious diseases whole organisms are expensive to produce, require culture of the infectious agent, and have the potential to cause vaccine associated disease in hosts. With advancing technology and a desire to develop safe, cost effective vaccine candidates, the field began to focus on the development of recombinantly expressed antigens known as subunit vaccines. While more tolerable, subunit vaccines tend to be less immunogenic. Attempts have been made to increase immunogenicity with the addition adjuvants, either immunostimulatory molecules or an antigen delivery system that increases immune responses to vaccines. An area of extreme interest has been the application of nanotechnology to vaccine development, which allows for antigens to be expressed on a particulate delivery system. One of the most exciting examples of nanovaccines are rationally designed protein nanoparticles. These nanoparticles use some of the basic tenants of structural biology, biophysical chemistry, and vaccinology to develop protective, safe, and easily manufactured vaccines. Rationally developed nanoparticle vaccines are one of the most promising candidates for the future of vaccine development.

show abstract

Oral Immunization with Helicobacter pylori‐Loaded Poly( d, l‐Lactide‐Co‐Glycolide) Nanoparticles

Abstract: Our results suggested that oral immunization of H. pylori-PLG nanoparticles induced the H. pylori-specific mucosal and systemic responses in mice and enhanced Th2-type responses.

Cited by 58 publications

References 35 publications

Past, Present, and Future Technologies for Oral Delivery of Therapeutic Proteins

Past, Present, and Future Technologies for Oral Delivery of Therapeutic Proteins

Mucosal vaccine delivery: Current state and a pediatric perspective

Vaccine technologies: From whole organisms to rationally designed protein assemblies

Contact Info

Product

Resources

About